ADAC, Eastern Isotopes form alliance
ADAC Laboratories has forged an exclusive vendor agreement with PET radiopharmaceutical manufacturer Eastern Isotopes. The partnership gives ADAC access to 5.5 millicurie doses of FDG, which it will buy at a discount from Eastern Isotopes, and allows it
ADAC Laboratories has forged an exclusive vendor agreement with PET radiopharmaceutical manufacturer Eastern Isotopes. The partnership gives ADAC access to 5.5 millicurie doses of FDG, which it will buy at a discount from Eastern Isotopes, and allows it to supply its molecular coincidence detection/attenuation correction (MCD/AC) and CPET customers. ADACs FDG imaging products do not require 10 millicurie doses of the radioisotope, as competitive products do, according to the Milpitas, CA, company.
Based in Sterling, VA, Eastern Isotopes was established in 1995 as a distributor of SPECT pharmaceuticals. Last year, the firm began to produce high-energy tracers, particularly FDG, for therapy, oncology, cardiology, and neurology.
With the deal, ADAC continues its push into the PET market, capitalizing on the momentum created by its September purchase of partner UGM Medical, a developer and manufacturer of PET devices (SCAN 9/29/99). The two firms codeveloped ADACs MCD high-energy imaging option for gamma cameras (SCAN 12/14/94).
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
Is MRI Contrast Enhancement Necessary for Long-Term Monitoring of Diffuse Glioma?
March 4th 2025In a comparison of contrast-enhanced T1-weighted (CET1w) MRI (and T2-weighted MRI/FLAIR imaging, researchers found that only three out of 82 cases of glioma progression were solely detected with CET1w MRI.
